WASHINGTON — Consultant pediatric neurologist Dr. Mohammed Al-Dosari, said the Cleveland Clinic Hospital is expected to meet the requirements of the US Food and Drug Administration (FDA) by the end of 2023 to adopt an innovative method for diagnosing autism in children.

Dr. Al-Dosari, director of the Pediatric Neurosciences Center at Cleveland Clinic Hospital, Ohio, US, said this can be done through an eye movement tracking device without having to rely on observations of family or specialists.

In a statement to the Saudi Press Agency (SPA), Dr. Al-Dosari said, that the center has tested the accuracy of the device in cooperation with several universities and prestigious US autism centers.

The center has also tested in several centers in the Gulf region, namely the Prince Mohammed Bin Salman Center for Autism and Growth Disorders in Riyadh, pointing out that the device is registered as a patent in the US for the Cleveland Clinic Innovation Center.

With this cutting-edge method, he added that autism will be diagnosed at an earlier age while also improving diagnostic accuracy, lowering costs, and maximizing competencies. — SPA